Monitoring Dynamic Growth of Retinal Vessels in Oxygen-Induced Retinopathy Mouse Model
April 2nd, 2021
This protocol describes a detailed method for the preparation and immunofluorescence staining of mice retinal flat mounts and analysis. The use of fluorescein fundus angiography (FFA) for mice pups and image processing are described in detail as well.
Overview
This protocol provides a comprehensive method for the preparation and immunofluorescence staining of retinal flat mounts from mice, focusing on observing dynamic changes in retinal vasculature in a model of oxygen-induced retinopathy. It emphasizes preservation of retinal integrity and allows each mouse to serve as its own control.
Key Study Components
Research Area
- Retinal biology
- Vascular changes in retinopathy
Background
- Retinal flat mounts are crucial for studying retinal structures and functions.
- Oxygen-induced retinopathy is a widely used model to examine retinal vascular development.
Methods Used
- Immunofluorescence staining and image processing techniques
- Mice (C57-Black/6) as the biological model
- Confocal fluorescence microscopy and fluorescein fundus angiography
Main Results
- Detailed steps for isolating retinas and conducting immunofluorescence staining.
- Identification of changes in vascular structures in response to experimental conditions.
- Visualization techniques confirmed the methodology's effectiveness for studying retinal disorders.
Conclusions
- This protocol enables researchers to effectively visualize and analyze the retinal vasculature in mice.
- It contributes valuable insights into the mechanisms underlying retinal diseases.
Frequently Asked Questions
Executive Industry Relevance
Dynamic monitoring of retinal vessel growth in the oxygen-induced retinopathy (OIR) mouse model provides critical insights for early-stage target validation in ischemic retinal diseases. Quantitative, time-resolved imaging of neovascularization and vaso-obliteration supports predictive confidence in translational research and informs risk-adjusted portfolio decisions for ophthalmic drug discovery. This protocol enables robust, reproducible assessment of vascular remodeling, directly impacting preclinical model selection and mechanistic de-risking.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables quantitative interrogation of therapeutic hypotheses in retinal neovascularization.
- Supports functional target validation by tracking vessel regrowth and regression dynamics.
- Facilitates mechanistic de-risking through direct visualization of disease-relevant vascular changes.
- Improves predictive confidence for advancing ophthalmic candidates.
Screening & Assay Development
- Establishes validated, reproducible imaging endpoints for downstream compound screening.
- Standardizes quantification of vaso-obliteration and neovascularization using immunofluorescence and FFA.
- Enables scalability and platform reuse for high-content screening of vascular modulators.
- Provides robust quantitative outputs for comparative evaluation of candidate interventions.
Translational & Preclinical Research
- Aligns preclinical model outputs with disease-relevant biomarkers observed in human retinopathies.
- Ensures continuity from discovery through preclinical validation by enabling longitudinal vessel monitoring.
- Supports risk-adjusted advancement decisions based on dynamic vascular remodeling data.
- Enhances translational relevance for therapies targeting retinal ischemia and neovascularization.
Pipeline & Workflow Integration
This protocol integrates from early discovery through preclinical research, bridging hypothesis testing, assay development, and translational validation in retinal disease models.
- Discovery Biology: Enables hypothesis-driven testing of angiogenic and anti-angiogenic mechanisms in vivo.
- Screening: Provides standardized, reproducible imaging and quantification workflows for candidate evaluation.
- Analytics: Delivers quantitative measurements of vessel area, diameter, and tortuosity for robust statistical comparison.
- Translational Research: Aligns preclinical vascular endpoints with clinical imaging biomarkers.
- Enterprise Reuse: Offers a reusable, validated platform for diverse retinal vascular research and drug discovery programs.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in retinal disease modeling.
- Operational Value: Standardizes imaging, quantification, and analysis for reproducible, scalable workflows.
- Strategic Value: Informs go/no-go decisions and enhances capital efficiency by de-risking early-stage candidates.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of ophthalmic assets.
Implementation Considerations
- Requires expertise in retinal dissection, immunofluorescence, and in vivo imaging techniques.
- Demands access to confocal microscopy, fundus angiography systems, and advanced image analysis software.
- Necessitates cross-team standardization of imaging protocols and quantification criteria.
- Adaptable to various mouse strains and retinal disease models with protocol optimization.
- Potential limitations include technical challenges in pup positioning and image stitching accuracy.
Biopharma FAQs
Chapters in this video
0:05
Introduction
0:58
Preparation of Retinal Whole Mounts and Immunofluorescence Staining
5:36
In Vivo Imaging with Fluorescein Fundus Angiography (FFA)
7:02
FAA Image Processing
8:40
Results: Vaso-Obliteration (VO) and Neovascularization (NV) in the Oxygen-Induced Retinopathy (OIR) Mouse Model
10:06
Conclusion
